ESMO 2018 | STAMPEDE: local radiotherapy improves survival in metastatic prostate cancer

Chris Parker

Update on the survival results from the STAMPEDE trial (NCT00268476), investigating radiotherapy to the primary tumour for men with newly-diagnosed metastatic prostate cancer. Presented by Chris Parker, BM, BChir, MD, FRCR, MRCP from the Royal Marsden NHS Foundation Trust, London, UK, at the prostate cancer press briefing at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany. Results showed that by treating the primary tumour with radiotherapy, there was a significant survival benefit in men with low metastatic burden.

Share this video